What is rapamycin?
Rapamycin (sirolimus) is a macrolide antibiotic discovered in 1972 on Easter Island (Rapa Nui). It inhibits the enzyme mTOR (mechanistic Target of Rapamycin) — a central growth regulator in cells. In medicine, it is approved as an immunosuppressant after organ transplantation and used in drug-eluting stents to prevent restenosis.
In longevity research, rapamycin is an outlier: it is the only compound that has consistently extended lifespan in multiple independent, high-quality animal studies.
What do the animal studies show?
The ITP program
The Interventions Testing Program (ITP), run by the US National Institute on Aging, tests compounds in genetically heterogeneous mice across three independent sites. Rapamycin is the clear star of this program:
- Harrison 2009: Lifespan extended by +9% (males) to +14% (females), even when started at 600 days of age
- Miller 2014: Dose-dependent effect confirmed — higher doses showed stronger effects
- Results have been replicated in yeast, worms, flies, and other mouse models
This is unique in longevity research. No other compound has such a consistent evidence base across animal models.
The mechanism: mTOR inhibition
mTOR is a cellular “growth switch.” When mTOR is active, cells build proteins, grow, and divide. When mTOR is inhibited:
- Autophagy is activated (cellular cleanup)
- Protein synthesis is reduced (fewer misfolded proteins)
- Stem cell function improves
- Inflammatory processes are dampened
These effects explain why mTOR inhibition extends lifespan across so many organisms. It is essentially a pharmacological equivalent of caloric restriction — the other robust longevity intervention.
What do the human studies show?
PEARL Trial (2023)
The first dedicated longevity RCT with rapamycin in humans. 40 healthy adults (ages 55–85) received 5 mg rapamycin weekly or placebo for 8 weeks.
Result: Well tolerated, no serious adverse events, no measurable immunosuppression at weekly dosing. The study was not powered for efficacy claims, but it provided important safety data.
Mannick 2014 (Immunosenescence)
218 adults over 65 received low-dose everolimus (a rapamycin analogue). After 6 weeks, the immune response to influenza vaccination improved by ~20% — direct evidence that mTOR inhibition can partially reverse age-related immune decline.
The off-label movement
A growing number of longevity physicians (mainly in the US) prescribe rapamycin off-label at low doses (typically 3–6 mg once weekly). This practice is based on animal evidence and initial safety data, but is not validated by large human trials.
Risks and side effects
Rapamycin is not a supplement — it is a potent drug with real risks:
- Immunosuppression at daily high doses (transplant doses)
- Hyperlipidemia: elevated cholesterol and triglycerides are the most consistent side effect
- Impaired wound healing with chronic use
- Oral mucositis (mouth ulcers) in ~20% of patients
- Diabetes risk: paradoxically, mTOR inhibition can worsen glucose tolerance
At weekly low-dose schedules, many of these side effects appear less frequent (PEARL data), but long-term data are lacking.
Prescription status and legal situation
Rapamycin is prescription-only in the EU and the US. There is no legal way to purchase it as a supplement. Online sources without prescription are legally questionable and quality-uncontrolled.
Verdict
Rapamycin is the scientifically best-supported longevity drug — but it is a drug, not a supplement. The animal data are uniquely strong, the initial human data encouraging, but clear recommendations for healthy humans await large, long-term RCTs. Anyone taking rapamycin off-label should do so only under medical supervision, with regular monitoring of lipids, blood glucose, and immune parameters.